Trending Stock News

$0.20 EPS Expected for Harsco (HSC); Credit Suisse Ag Has Decreased By $1.69 Million Its Nektar Therapeutics (NKTR) Holding

Harsco Corporation (NYSE:HSC) Logo

Credit Suisse Ag decreased Nektar Therapeutics (NKTR) stake by 7.84% reported in 2017Q4 SEC filing. Credit Suisse Ag sold 28,721 shares as Nektar Therapeutics (NKTR)’s stock rose 80.22%. The Credit Suisse Ag holds 337,785 shares with $20.17M value, down from 366,506 last quarter. Nektar Therapeutics now has $13.87 billion valuation. The stock decreased 4.37% or $3.94 during the last trading session, reaching $86.21. About 3.09M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since April 23, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

Analysts expect Harsco Corporation (NYSE:HSC) to report $0.20 EPS on May, 2 before the open.They anticipate $0.09 EPS change or 81.82% from last quarter’s $0.11 EPS. HSC’s profit would be $16.09 million giving it 27.50 P/E if the $0.20 EPS is correct. After having $0.20 EPS previously, Harsco Corporation’s analysts see 0.00% EPS growth. The stock decreased 0.90% or $0.2 during the last trading session, reaching $22. About 407,784 shares traded. Harsco Corporation (NYSE:HSC) has risen 69.83% since April 23, 2017 and is uptrending. It has outperformed by 58.28% the S&P500.

Investors sentiment decreased to 1.19 in Q4 2017. Its down 0.21, from 1.4 in 2017Q3. It turned negative, as 18 investors sold NKTR shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported. Miles has 8,383 shares. Westfield Cap Management Ltd Partnership has 1.05% invested in Nektar Therapeutics (NASDAQ:NKTR). Guggenheim Limited Company invested in 151,055 shares or 0.02% of the stock. Opaleye Inc holds 1.53% or 80,000 shares in its portfolio. Savings Bank Of Montreal Can holds 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 7,252 shares. Pinebridge LP accumulated 129,592 shares. Clarivest Asset Management Ltd Liability has invested 0.05% in Nektar Therapeutics (NASDAQ:NKTR). Qs Investors Limited Liability Corp reported 3,612 shares stake. Susquehanna Intl Limited Liability Partnership stated it has 0.02% in Nektar Therapeutics (NASDAQ:NKTR). 85,265 were accumulated by Putnam Invests Lc. Fiera accumulated 136,981 shares. Renaissance Lc, a New York-based fund reported 91,848 shares. Manitoba – Canada-based Great West Life Assurance Can has invested 0.03% in Nektar Therapeutics (NASDAQ:NKTR). Minnesota-based Thrivent For Lutherans has invested 0.02% in Nektar Therapeutics (NASDAQ:NKTR). Bankshares Of America De reported 383,787 shares.

Credit Suisse Ag increased Alibaba Group Hldg Ltd (Put) (NYSE:BABA) stake by 1.14M shares to 1.75 million valued at $301.80M in 2017Q4. It also upped Vaneck Vectors Etf Tr (Call) stake by 447,900 shares and now owns 1.52M shares. Equifax Inc (NYSE:EFX) was raised too.

Since December 13, 2017, it had 0 insider buys, and 18 selling transactions for $68.39 million activity. 2,426 shares valued at $201,212 were sold by Doberstein Stephen K on Friday, February 16. Labrucherie Gil M sold 3,477 shares worth $288,382. KUEBLER CHRISTOPHER A had sold 30,000 shares worth $1.76M on Tuesday, January 2. ROBIN HOWARD W sold 12,788 shares worth $1.06 million. The insider CHESS ROBERT sold $2.30 million. Thomsen Jillian B. also sold $1.41M worth of Nektar Therapeutics (NASDAQ:NKTR) shares. The insider Hora Maninder sold 29,498 shares worth $3.03 million.

Among 11 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 27 analyst reports since August 6, 2015 according to SRatingsIntel. Roth Capital maintained the stock with “Buy” rating in Thursday, July 20 report. The firm earned “Overweight” rating on Thursday, January 7 by Piper Jaffray. As per Wednesday, August 9, the company rating was maintained by Roth Capital. H.C. Wainwright reinitiated the stock with “Buy” rating in Monday, April 2 report. The firm has “Hold” rating by TheStreet given on Wednesday, August 26. Jefferies maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Wednesday, August 16. Jefferies has “Buy” rating and $23.0 target. The company was initiated on Thursday, November 9 by Canaccord Genuity. Jefferies maintained Nektar Therapeutics (NASDAQ:NKTR) on Wednesday, October 18 with “Buy” rating. Roth Capital maintained Nektar Therapeutics (NASDAQ:NKTR) on Wednesday, August 30 with “Buy” rating. Roth Capital maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Monday, November 13. Roth Capital has “Buy” rating and $45.0 target.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on May, 8. They expect $-0.43 earnings per share, down 2.38% or $0.01 from last year’s $-0.42 per share. After $-0.14 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts 207.14% negative EPS growth.

Among 5 analysts covering Harsco Corporation (NYSE:HSC), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Harsco Corporation had 12 analyst reports since August 17, 2015 according to SRatingsIntel. The stock of Harsco Corporation (NYSE:HSC) earned “Buy” rating by Jefferies on Thursday, June 15. The rating was initiated by Lake Street with “Buy” on Tuesday, September 13. KeyBanc Capital Markets maintained Harsco Corporation (NYSE:HSC) on Wednesday, February 28 with “Overweight” rating. The rating was upgraded by Argus Research on Friday, September 15 to “Buy”. Jefferies maintained Harsco Corporation (NYSE:HSC) rating on Thursday, August 3. Jefferies has “Buy” rating and $1900 target. The stock of Harsco Corporation (NYSE:HSC) has “Overweight” rating given on Wednesday, October 7 by KeyBanc Capital Markets. The rating was maintained by KeyBanc Capital Markets on Friday, November 10 with “Buy”. The stock has “Overweight” rating by KeyBanc Capital Markets on Monday, August 17.

Harsco Corporation provides industrial services and engineered products worldwide. The company has market cap of $1.77 billion. The firm operates through three divisions: Harsco Metals & Minerals, Harsco Industrial, and Harsco Rail. It has a 239.13 P/E ratio. The Harsco Metals & Minerals segment provides on-site services of material logistics, product quality improvement, and resource recovery for iron, steel, and metals manufacturing; and value added environmental solutions for industrial co-products, as well as makes industrial abrasives and roofing granules.

Harsco Corporation (NYSE:HSC) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *